Soligenix's HyBryte™ Demonstrates Promising Results in Rare Skin Cancer Treatment

Soligenix has reported significant progress in developing HyBryte™, a novel treatment for cutaneous T-cell lymphoma (CTCL), demonstrating a 75% response rate in early clinical trials. The therapy offers hope for patients with this rare and challenging skin cancer, with six out of eight patients showing major improvement in skin lesions after 18 weeks.

The treatment's unique approach uses visible light instead of harmful UV radiation, potentially addressing key limitations in current CTCL therapies. Unlike existing treatments that can take 6-12 months to work and carry substantial side effect risks, HyBryte™ appears to work faster and safer, with three patients achieving complete lesion resolution.

The FDA has recognized the treatment's potential, providing a $2.6 million grant through its Orphan Products Development program. This support underscores the therapy's promising clinical profile and potential to address an unmet medical need.

CTCL represents a significant market opportunity, with approximately 3,000 new cases annually in the United States and up to 30,000 patients living with the chronic condition. The disease predominantly affects men over 50, with incidence increasing substantially by age 70. With limited effective treatment options, HyBryte™ could capture substantial market share if approved.

Soligenix is currently enrolling patients in a confirmatory Phase 3 FLASH2 trial, with potential expanded applications including home-based treatment. The therapy's development represents a critical advancement in managing a challenging and currently incurable disease.